CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 10303-10306
10.1182/blood-2022-166432